Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhihui Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Beilong Zhong

    Department of Thoracic Surgery, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong 519000, China

    2 shared publications
  • Bing-Hua Jiang

    Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan 450000, China

    1 shared publication
  • Fei Tong

    Center for Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China

    1 shared publication
  • Hongcheng Zhong

    Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China

    1 shared publication
  • Hongyu Zhang

    Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China

    1 shared publication
  • Jae Jun Kim

    Department of Thoracic and Cardiovascular Surgery, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea

    1 shared publication

Latest Publications

  • Open Access

    Ozonated water mouthrinse for radiation-induced oral mucositis in non-keratinizing nasopharyngeal carcinoma: a retrospective cohort study

    by Jing Yu, Xueqing Ou, Fei Tong, Qiuyan Su, Wushuang Zeng, Zhihui Wang, Xiaojian Li

    Purpose To evaluate the association between documented ozonated water (OW) mouthrinsing and radiotherapy-induced oral mucositis (OM) outcomes in patients with nasopharyngeal carcinoma (NPC). Methods A single-center retrospective cohort study included 65 NPC patients receiving definitive chemoradiotherapy. Among them, 34 had documented OW mouthrinsing during radiotherapy and 31 served as controls without documented OW use. The primary endpoint was time to first WHO grade ≥ 2 OM. Because OW initiation was time-varying, time-dependent Cox and landmark analyses were used as the main time-aware approaches, with propensity score–based models retained as supportive association analyses. Secondary outcomes included the incidence of grade ≥ 2 OM at fractions 15 and 30, peak oral pain scores, and post-EoRT mucosal healing interval. Results OW initiation occurred at a median fraction of 2.5 (IQR 1–4.75; range F1–F22). In time-aware analyses, documented OW exposure was associated with a lower hazard of first grade ≥ 2 OM in both the time-dependent Cox model (HR 0.35, 95% CI 0.20–0.63; P < 0.001) and the 10-fraction landmark analysis (HR 0.47, 95% CI 0.26–0.83; P = 0.010). Supportive fixed ever-use propensity score–based analyses were directionally consistent, including the stabilized IPTW model (HR 0.48, 95% CI 0.27–0.88; P = 0.018). At fraction 30, 50.0% of OW patients versus 90.3% of controls had grade ≥ 2 OM. The OW group also reported lower peak oral pain (P < 0.01) and a nonsignificant trend toward a shorter post-EoRT mucosal healing interval. Conclusion Documented OW mouthrinsing during radiotherapy was associated with lower OM burden and reduced oral pain in this retrospective NPC cohort. Given the observational design, time-varying exposure, residual confounding, and chart-based exposure and outcome ascertainment, these findings should be interpreted as exploratory associations requiring prospective validation.

  • Open Access

    Investigating the role of TIMM8B in lung adenocarcinoma: Expression patterns, prognostic value, and therapeutic implications

    by Zhuli Zheng, Libao Gong, Hongcheng Zhong, Bingjiang Huang, Yunyan Cong, Beilong Zhong, Zhihui Wang

    Introduction: Translocase of inner mitochondrial membrane 8 homolog B (TIMM8B) is crucial for mitochondrial function, but its role in lung adenocarcinoma (LUAD) remains underexplored. Objective: This study investigates TIMM8B expression patterns, prognostic value, and potential therapeutic implications in LUAD. Methods: The expression and prognostic potential of TIMM8B in LUAD were analyzed using data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression, Gene Expression Omnibus, and Gene Expression Profiling Interactive Analysis 2, with survival analysis performed through Kaplan–Meier plotter. The prognostic value was validated using a LUAD tissue microarray and a nomogram. TIMM8B-related differentially expressed genes were identified using TCGA and LinkedOmics, and were functionally annotated using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. Immunological features were assessed using TCGA data through the XCELL and tumor immune dysfunction and exclusion algorithms. Associations among TIMM8B, m6A modification, ferroptosis-related genes, and tumor genetic mutations were analyzed using TCGA data. Drug response correlations were explored using the Genomics of Drug Sensitivity in Cancer and Comparative Toxicogenomics databases. TIMM8B-depleted LUAD cell lines were analyzed using ribonucleic acid sequencing and subjected to cell cycle analysis. Results: TIMM8B is overexpressed in multiple cancers, including LUAD. High TIMM8B expression correlates with poorer overall survival in LUAD. A nomogram incorporating TIMM8B and pathological tumor-node-metastasis stage showed reliable predictive performance. TIMM8B-related gene analyses suggest roles in cell adhesion, chromosome segregation, and critical cancer pathways. TIMM8B shapes an immunosuppressive tumor microenvironment in LUAD, affecting immune cell infiltration and immunotherapy response. Elevated TIMM8B expression is associated with TP53 mutations and chemotherapy resistance. Knockdown of TIMM8B in H1299 cells downregulates PD-L1, induces G1 phase arrest, and triggers a chemokine (C-C motif) ligand 2-mediated inflammatory response, highlighting roles in cell cycle regulation and inflammatory pathways. Conclusion: These findings underscore TIMM8B’s multifaceted role in cancer progression and its potential as a prognostic marker and therapeutic target in LUAD.


  • Open Access

    Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer

    by Weize Lv, Xiaofeng Pei, Wenhua Zhao, Yunyan Cong, Yajun Wei, Ting Li, Hongyu Zhang, Zhong Lin, Yuichi Saito, Jae Jun Kim, et al.

    Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer Weize Lv, Xiaofeng Pei, Wenhua Zhao, Yunyan Cong, Yajun Wei, Ting Li, Hongyu Zhang, Zhong Lin, Yuichi Saito, Jae Jun Kim, Zibin Liang, Beilong Zhong, Zhihui Wang